Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 03, 2022 |
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 2,583,658 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.94 · Expires 2030-04-29 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.24 · Expires 2029-05-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Serina Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,897,445 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Conversion · Acquired 1,770,805 · Balance 1,897,445 F1: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026. F2: The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 8,564,382 |
Reported balance
After 2026-06-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-17 · Conversion · Acquired 6,666,667 · Balance 8,564,382 F3: Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2036-06-17 | Direct | 15,250 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 15,250 · Balance 15,250 F4: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
| Redeemable WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2030-03-17 | Direct | 3,333,333 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 3,333,333 · Balance 3,333,333 F5: Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.18 | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-17 · Conversion · Disposed 762,548 · Balance 0 F6: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026.
F2: The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person.
F3: Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock.
F4: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
F5: Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice.
F6: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 11,975 | $7.50 | $89,812.50 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 6 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307,971 F2 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 9,000 | $3.06 | $27,540.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 5 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,319,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 9,000 | $2.33 | $20,970.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,310,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 5,998 | $3.56 | $21,352.88 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,295,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 1,291,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291,829 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | PurchaseCommon Stock | 38,000 | $148.04 | $5,625,675.80 |
DisclosureSEC source: 0001562180-22-006259 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,583,658 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $147.98 - $148.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 20:59 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 8,239 | $0.00 Strike: $97.74 | $0.00 |
DisclosureSEC source: 0001562180-22-003584 · primarydocument.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,239 Underlying: Common Shares · 8,239 shares Expires 2032-04-27 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2023 or (b) the date of the 2023 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| June 21, 2021 Filed Jun 24, 2021 01:52 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Purchase Common Stock · Derivative | 65,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001209191-21-042898 · doc4.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-06-20 F1 · derivative.exercise_date: Options will vest and become exercisable in four equal quarterly installments on June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:34 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 11,996 | $0.00 Strike: $71.94 | $0.00 |
DisclosureSEC source: 0001562180-21-003338 · primarydocument.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,996 Underlying: Common Shares · 11,996 shares Expires 2031-05-04 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2022 or (b) the date of the 2022 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 21:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 212 | $79.94 | $16,948.00 |
DisclosureSEC source: 0001562180-20-006429 · primarydocument.xml · nonDerivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,545,658 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.89 - $80.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 21:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 10,191 | $78.89 | $803,918.05 |
DisclosureSEC source: 0001562180-20-006429 · primarydocument.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,545,870 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.80 - $79.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 21:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 3,100 | $79.88 | $247,632.03 |
DisclosureSEC source: 0001562180-20-006429 · primarydocument.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,556,061 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.83 - $79.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 21:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 21,466 | $79.41 | $1,704,720.24 |
DisclosureSEC source: 0001562180-20-006429 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,559,161 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.83 - $79.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 19, 2020 Filed Oct 21, 2020 21:24 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 4,554 | $78.98 | $359,655.34 |
DisclosureSEC source: 0001562180-20-006406 · primarydocument.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,580,627 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.80 - $79.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2020 Filed Oct 21, 2020 21:24 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 3,748 | $78.88 | $295,638.12 |
DisclosureSEC source: 0001562180-20-006406 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,585,181 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.80 - $79.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 21:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 6,729 | $78.87 | $530,740.45 |
DisclosureSEC source: 0001562180-20-006368 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,588,929 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.80 - $79.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:16 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 5,991 | $75.93 | $454,888.24 |
DisclosureSEC source: 0001562180-20-005101 · primarydocument.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595,658 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.84 - $76.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:16 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 44,009 | $75.12 | $3,305,876.86 |
DisclosureSEC source: 0001562180-20-005101 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,601,649 F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.81 - $75.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 21:49 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 2,395 | $70.24 | $168,224.80 |
DisclosureSEC source: 0001562180-20-004698 · primarydocument.xml · nonDerivative · entry 6 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,645,658 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.84 - $70.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 21:49 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 1,600 | $69.29 | $110,864.96 |
DisclosureSEC source: 0001562180-20-004698 · primarydocument.xml · nonDerivative · entry 5 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648,053 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.83 - $69.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:49 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 835 | $75.18 | $62,779.31 |
DisclosureSEC source: 0001562180-20-004698 · primarydocument.xml · nonDerivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,649,653 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.15 - $75.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:49 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 63,257 | $74.60 | $4,719,256.86 |
DisclosureSEC source: 0001562180-20-004698 · primarydocument.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,650,488 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.14 - $75.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:49 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 24,084 | $73.72 | $1,775,368.92 |
DisclosureSEC source: 0001562180-20-004698 · primarydocument.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,713,745 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.14 - $74.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:49 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 13,467 | $72.70 | $979,026.66 |
DisclosureSEC source: 0001562180-20-004698 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,737,829 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.14 - $73.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 49,132 | $73.64 | $3,618,011.70 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 10 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,751,296 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.41 - $74.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 20,659 | $72.91 | $1,506,202.24 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 9 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800,428 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.41 - $73.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 10,540 | $72.01 | $758,961.16 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 8 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,821,087 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.41 - $72.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 428 | $75.22 | $32,193.39 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 7 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,831,627 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.86 - $75.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 22,584 | $73.78 | $1,666,267.85 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 6 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,832,055 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.48 - $74.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 12,157 | $72.93 | $886,618.52 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 5 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,854,639 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.47 - $73.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 21,798 | $71.98 | $1,568,935.03 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,866,796 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.47 - $72.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 58,238 | $70.91 | $4,129,854.59 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,888,594 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.46 - $71.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 26,814 | $70.10 | $1,879,792.79 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,946,832 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.46 - $70.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 21:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 22,012 | $69.01 | $1,519,094.35 |
DisclosureSEC source: 0001562180-20-004629 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973,646 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.46 - $69.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to Buy) · Derivative | 212,500 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · derivative · entry 11 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 212,500 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on November 26, 2014, with the remainder vesting in 3 equal installments on the first, second and third anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · derivative · entry 10 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 150,000 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on October 23, 2015, with the remainder vesting in 3 equal installments on the first, second and third anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (right to buy) · Derivative | 37,700 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · derivative · entry 9 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 37,700 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on December 15, 2016, with the remainder vesting in 3 equal installments on the first, second and third anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · derivative · entry 8 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on April 6, 2017, with the remainder vesting in 3 equal installments on the first, second and third anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $28.76 | $0.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · derivative · entry 7 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2028-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this stock option vested in full on May 1, 2019. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Tax withholdingCommon Shares | 30,143 | $68.15 | $2,054,245.45 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · nonDerivative · entry 6 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,995,658 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy the option exercise price. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 18,000 | $28.76 | $517,680.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · nonDerivative · entry 5 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,025,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 20,000 | $10.82 | $216,400.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · nonDerivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 37,700 | $9.29 | $350,233.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,987,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 150,000 | $5.60 | $840,000.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,950,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:15 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 212,500 | $0.61 | $129,625.00 |
DisclosureSEC source: 0001562180-20-004321 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:14 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $47.10 | $0.00 |
DisclosureSEC source: 0001562180-20-003258 · primarydocument.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2030-04-29 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2021 or (b) the date of the 2021 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 16:11 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | PurchaseCommon Shares | 5,000 | $37.65 | $188,250.00 |
DisclosureSEC source: 0001689813-19-000061 · wf-form4_156641827534102.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,587,601 Read SEC document |
| May 21, 2019 Filed May 23, 2019 18:35 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $61.76 | $0.00 |
DisclosureSEC source: 0001209191-19-032466 · doc4.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2029-05-20 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 21, 2020 or (b) the date of the 2020 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| March 25, 2019 Filed Apr 5, 2019 17:54 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionWarrant to Purchase Common Shares (Right to Buy) · Derivative | 107,500 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001209191-19-023860 · doc4.xml · derivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 107,500 shares Expires 2019-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.